FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

SLU-PP-332

ERR alpha agonist

Weight Loss & Metabolic

SLU-PP-332 is a small molecule agonist of the estrogen-related receptors (ERRs), particularly ERR-alpha and ERR-gamma, developed at Saint Louis University as an exercise mimetic that enhances muscle endurance and fatigue resistance without physical training. It is not technically a peptide but a synthetic small molecule that activates transcription factors controlling mitochondrial biogenesis, oxidative metabolism, and muscle fiber type composition. Published in 2023, it represents one of the newest entries in the exercise mimetic compound class and remains in very early preclinical development.

作用機序

ERRa agonist that mimics the transcriptional effects of exercise. Activates mitochondrial biogenesis and oxidative metabolism pathways.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols limited to animal studies. Mouse models used 25-50mg/kg. No established human dosing.

研究ノート

Clinical Research Status

SLU-PP-332 was first published in the Journal of Pharmacology and Experimental Therapeutics in 2023 by researchers at Saint Louis University, representing extremely early-stage preclinical research with only animal data available. No clinical trials have been registered or planned for human testing, and the compound remains purely a research tool for understanding ERR biology and exercise physiology. Its emergence has generated media attention as a potential "exercise in a pill" compound, though such applications remain speculative and distant from clinical reality.

Key Published Findings

Mouse studies demonstrate that SLU-PP-332 administration increased running endurance by approximately 50% on treadmill exhaustion tests and enhanced fatigue-resistant oxidative (Type I and IIa) muscle fiber proportions without exercise training. The compound activates ERR-alpha and ERR-gamma transcription factors, which are master regulators of mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation gene programs in skeletal muscle. Treated animals showed increased muscle mitochondrial density, enhanced oxidative capacity, and gene expression profiles resembling those of trained athletes.

Safety Profile

Formal toxicology studies have not been published, and the safety profile of SLU-PP-332 in any species is largely unknown beyond the limited animal experiments reported. ERR receptors are expressed in multiple tissues including heart, kidney, and brain, raising theoretical concerns about off-target effects from systemic ERR activation. The structural novelty of the compound means there is no existing clinical safety data from related molecules to extrapolate from, unlike older exercise mimetics with more established safety profiles.

Comparison to Related Compounds

SLU-PP-332 targets a different pathway than AICAR (AMPK activation) or GW501516 (PPAR-delta activation), representing a third distinct molecular approach to exercise mimicry through the ERR transcription factor family. While GW501516 demonstrated concerning carcinogenicity in long-term animal studies, whether ERR agonism carries similar risks is unknown due to the early stage of research. Unlike both AICAR and GW501516 which have years of research history and some human data, SLU-PP-332 has only a single primary publication and minimal characterization.

Community Observations

Interest in SLU-PP-332 has been driven primarily by mainstream media coverage framing it as an "exercise pill," generating excitement in fitness and longevity communities. The compound is not commercially available from any legitimate source as of current reports, and anyone claiming to sell it likely cannot verify identity or purity. Experienced researchers in the performance enhancement space advise patience, noting that the journey from initial publication to any form of human-ready compound typically spans 10-15 years of development.

半減期

~4-6 hours

再構成

DMSO or appropriate vehicle

保存

乾燥粉末

Store at -20C. Protect from light and moisture.

再溶解

Store at -20C in solution.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

ERR alpha agonist

よくある質問

SLU-PP-332とは何ですか?

SLU-PP-332 is a small molecule agonist of the estrogen-related receptors (ERRs), particularly ERR-alpha and ERR-gamma, developed at Saint Louis University as an exercise mimetic that enhances muscle endurance and fatigue resistance without physical training. It is not technically a peptide but a synthetic small molecule that activates transcription factors controlling mitochondrial biogenesis, oxidative metabolism, and muscle fiber type composition. Published in 2023, it represents one of the newest entries in the exercise mimetic compound class and remains in very early preclinical development.

SLU-PP-332はどのように作用しますか?

ERRa agonist that mimics the transcriptional effects of exercise. Activates mitochondrial biogenesis and oxidative metabolism pathways.

SLU-PP-332の米国での規制状況は?

Research chemical (not FDA-approved)

SLU-PP-332の半減期は?

~4-6 hours

SLU-PP-332の別名は?

ERR alpha agonist

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む